Nkarta to Participate in Upcoming Investor Conference

Group 1 - Nkarta, Inc. is participating in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 12:30 p.m. ET, featuring a fireside chat [1] - A simultaneous webcast of the event will be available on Nkarta's website, with a replay archived for approximately 90 days [1] Group 2 - Nkarta is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies [2] - The company utilizes a cell expansion and cryopreservation platform combined with proprietary cell engineering technologies and CRISPR-based genome engineering to create a pipeline of future cell therapies [2] - Nkarta aims to provide therapies engineered for deep therapeutic activity and intended for broad access in outpatient treatment settings [2]